Novel Antischizophrenia Treatments (handbook Of Experimental Pharmacology)

This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications. Front Matter....Pages i-x Clinical Instruments to Evaluate and Guide Treatment in Schizophrenia....Pages 1-10 Cognitive Impairment in Schizophrenia....Pages 11-37 Behavioral Animal Models to Assess Pro-cognitive Treatments for Schizophrenia....Pages 39-79 Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia....Pages 81-111 Mutant Mouse Models in Evaluating Novel Approaches to Antipsychotic Treatment....Pages 113-145 5-HT 2C Agonists as Therapeutics for the Treatment of Schizophrenia....Pages 147-165 The Role of Dopamine D 3 Receptors in Antipsychotic Activity and Cognitive Functions....Pages 167-210 Nicotinic Mechanisms in the Treatment of Psychotic Disorders: A Focus on the α7 Nicotinic Receptor....Pages 211-232 Muscarinic Mechanisms in Psychotic Disorders....Pages 233-265 Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications....Pages 267-295 Metabotropic Glutamate Receptors for New Treatments in Schizophrenia....Pages 297-365 Glycine Transport Inhibitors in the Treatment of Schizophrenia....Pages 367-399 Nicotinic Receptors and Functional Regulation of GABA Cell Microcircuitry in Bipolar Disorder and Schizophrenia....Pages 401-417 Development of Disease-Modifying Treatment of Schizophrenia....Pages 419-442 Back Matter....Pages 443-455 Annotation This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume will concentrate on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications